Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 6/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | HTR1E | P28566 | 1/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.41 |
| ▸ | BLM | P54132 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 2/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1287308 | 0.84 | CYP2D6 (0.46) | CYP2D6MAPK1HTTLMNACYP1A2 | |
| SCHEMBL1491633 | 0.83 | CYP2D6 (0.50) | CYP2D6HTTCHRM2CHRM1LMNA | |
| SCHEMBL1491629 | 0.83 | CYP2D6 (0.50) | CYP2D6HTTCHRM2CHRM1LMNA | |
| SCHEMBL8199654 | 0.83 | CYP2D6 (0.50) | CYP2D6HTTCHRM2CHRM1LMNA | |
| SCHEMBL2539307 | 0.83 | TYR (0.50) | CYP2D6MAPK1LMNACYP1A2CYP2C9 | |
| SCHEMBL1287302 | 0.83 | CYP2D6 (0.45) | CYP2D6MAPK1HTTCHRM2CHRM1 | |
| SCHEMBL1287218 | 0.82 | TYR (0.49) | CYP2D6MAPK1LMNACYP1A2CYP2C9 | |
| SCHEMBL720340 | 0.82 | CYP2D6 (0.49) | CYP2D6HTTCHRM2CHRM1LMNA | |
| Cyclopentane SCHEMBL4965591 | 0.82 | CYP2D6 (0.49) | CYP2D6HTTCHRM2CHRM1LMNA | |
| SCHEMBL720740 | 0.82 | CYP2D6 (0.49) | CYP2D6HTTCHRM2CHRM1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2013175-B9 | p38 MAP KINASE INHIBITORS | MACROPHAGE PHARMA LTD (GB) | 2020-11-11 | — | — | EP | disclosed |
| EP-2013175-B1 | p38 MAP KINASE INHIBITORS | CHROMA THERAPEUTICS LTD (GB) | 2016-11-09 | — | — | EP | disclosed |
| US-8962825-B2 | Hydroxamates as inhibitors of histone deacetylase | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-02-24 | — | — | US | disclosed |
| EP-2077999-B1 | HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE | CHROMA THERAPEUTICS LTD (GB) | 2014-07-30 | — | — | EP | disclosed |
| US-8044211-B2 | P38 MAP kinase inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2011-10-25 | — | — | US | disclosed |
| US-20100317678-A1 | HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE | CHROMA THERAPEUTICS LTD. (GB) | 2010-12-16 | — | — | US | disclosed |
| US-20100267774-A1 | P38 MAP KINASE INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2010-10-21 | — | — | US | disclosed |
| EP-2077999-A1 | HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE | Chroma Therapeutics Limited (GB) | 2009-07-15 | — | — | EP | disclosed |
| US-20090099185-A1 | P38 Map Kinase Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2009-04-16 | — | — | US | disclosed |
| WO-2008053131-A1 | HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE | CHROMA THERAPEUTICS LTD. (GB) | 2008-05-08 | — | — | WO | disclosed |
| WO-2008053158-A1 | INHIBITORS OF P38 MITOGEN-ACTIVATED PROTEIN KINASE | CHROMA THERAPEUTICS LTD. (GB) | 2008-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317678-A1 | HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE | H1-2, HDAC1, H1-0 | CYP2D6 1891/4885MAPK1 1045/4885HTT 1796/4885 |
| US-20090099185-A1 | P38 Map Kinase Inhibitors | MAPK1, CNKSR1, MAPK3 | CYP2D6 1270/4885MAPK1 1/4885HTT 4507/4885 |
| US-20100267774-A1 | P38 MAP KINASE INHIBITORS | MAPK1, MAPK3, MAPK12 | CYP2D6 1189/4885MAPK1 1/4885HTT 4647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.